Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.
about
Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer.Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathwayKRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma.Targeting cytokine therapy to the pancreatic tumor microenvironment using PD-L1 specific VHHs.Genetic dissection of the miR-200-Zeb1 axis reveals its importance in tumor differentiation and invasion
P2860
Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Genetically Engineered Mouse M ...... mmuno-oncology Drug Discovery.
@en
Genetically Engineered Mouse M ...... mmuno-oncology Drug Discovery.
@nl
type
label
Genetically Engineered Mouse M ...... mmuno-oncology Drug Discovery.
@en
Genetically Engineered Mouse M ...... mmuno-oncology Drug Discovery.
@nl
prefLabel
Genetically Engineered Mouse M ...... mmuno-oncology Drug Discovery.
@en
Genetically Engineered Mouse M ...... mmuno-oncology Drug Discovery.
@nl
P2093
P2860
P356
P1476
Genetically Engineered Mouse M ...... Immuno-oncology Drug Discovery
@en
P2093
Chad A Komar
Fee Bengsch
Kathleen Graham
P2860
P304
14.39.1-14.39.20
P356
10.1002/CPPH.2
P577
2016-06-01T00:00:00Z